Company Performance Metrics
- Ildiko Csiki: Chief Medical OfficerPast Role: Inovio Pharmaceuticals, Vice President Clinical Development Immuno- Oncology
- Jean Campbell: Vice President of Biologics Discovery
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery of
medicines that alter the treatment landscape and contributing value to patients and society.
Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems.
Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA.
